Melanoma Cancer section

Melanoma News & Features

Sequential Immunotherapy, Targeted Therapy Linked to Cutaneous Adverse Events in Advanced Melanoma

Sequential Immunotherapy, Targeted Therapy Linked to Cutaneous Adverse Events in Advanced Melanoma

Results of a retrospective chart review of patients with BRAF-mutant metastatic melanoma receiving sequential treatment with immunotherapy and targeted therapy or vice versa are presented.

Number of Cutaneous Nevi Associated With Mortality Risk in Melanoma, Particularly for Men

Number of Cutaneous Nevi Associated With Mortality Risk in Melanoma, Particularly for Men

An epidemiologic study shows that the number of cutaneous nevi may be a better independent predictor of melanoma death in men compared with women.

Melanoma Survival Varies Among U.S. States

Melanoma Survival Varies Among U.S. States

The number of physicians in a state and melanoma incidence were factors in melanoma mortality, researchers found.

Quick Take: Phase Ib/II Study of Pembrolizumab and Pegylated Interferon Alfa-2b in Advanced Melanoma

Programmed death-1 (PD-1) inhibitors have shown efficacy in the treatment of melanoma. Pre-existing CD8+ T-cell infiltrate and interferon (IFN) gene signature has been shown to correlate with response to PD-1 blockade. As such, the receipt of combination therapy with interferon (IFN) may enhance anti-tumor effects. In this open-label phase Ib/II trial, investigators treated 43 patients []

AAD Releases New Guidelines for the Treatment of Cutaneous Melanoma

AAD Releases New Guidelines for the Treatment of Cutaneous Melanoma

Guidelines recommend surgical excision as primary treatment modality, and emphasize individualized care.

CheckMate 067 Gives Nivolumab Alone, With Ipilimumab the Nod in Advanced Melanoma

CheckMate 067 Gives Nivolumab Alone, With Ipilimumab the Nod in Advanced Melanoma

Survival and progression-free survival were better with nivolumab alone or with ipilimumab vs ipilimumab alone for stage III or IV melanoma with known BRAFV600 mutation, according to results of this randomized study.

Novel Immunotherapy May Increase Survival in Melanoma Brain Metastases

Novel Immunotherapy May Increase Survival in Melanoma Brain Metastases

Researchers used data from the National Cancer Database to evaluate the overall survival of patients who presented with cutaneous MBM from 2010 to 2015.

SD-101 May Enhance the Effectiveness of Immunotherapy in Melanoma

SD-101 May Enhance the Effectiveness of Immunotherapy in Melanoma

In this phase 1b study, researchers evaluated the efficacy of immunotherapy with pembrolizumab to treat advanced melanoma.

Red Hair Variants of MC1R Influence Melanoma Risk Differently in Men, Women

Red Hair Variants of MC1R Influence Melanoma Risk Differently in Men, Women

Multivariate logistic regression analyses were utilized by researchers to evaluate the effect of MC1R and melanoma risk in men vs women.

Assessing Direct Costs of Treatment-Related Adverse Events in Advanced Melanoma

Assessing Direct Costs of Treatment-Related Adverse Events in Advanced Melanoma

In a systematic review, researchers explored the financial burden of treating grade 3 to 4 adverse events associated with melanoma and its treatment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs